论文部分内容阅读
α-干扰素治疗慢性丙型肝炎时有些病人起初ALT下降,但继续治疗中又复上升,此现象称之为反跳(breakthrough)。作者复习了自己的经验以说明此现象的发生率、发生机制、恰当的处理及转归。 方法:共71例慢性丙肝病人均采用干扰素α-2b治疗。40例开始剂量为每周3次,每次2MU,治疗6~8周后.ALT仍不正常者,剂量增至每次5MU。若ALT下降至少51%而病人能耐受者,则疗程持续一年。其余病人采用干扰素每周3次,每次2~3MU治疗,持续6个月,是否增加剂量或继续用药由医生决定。至
Interferon alpha in the treatment of chronic hepatitis C Some patients initially decreased ALT, but continue to rise again in the treatment, this phenomenon is called breakthrough (breakthrough). The author reviews his own experience to illustrate the incidence of this phenomenon, its mechanism, its proper handling and its outcome. Methods: A total of 71 patients with chronic hepatitis C were treated with interferon α-2b. Forty patients started 3 times a week with 2 MU each time, and after 6 to 8 weeks of treatment, the ALT was still abnormal and the dose was increased to 5 MU each time. If the ALT dropped by at least 51% and the patient can tolerate, the course of treatment lasts one year. The remaining patients with interferon 3 times a week, each 2 ~ 3MU treatment for 6 months, whether to increase the dose or continue to medication by the doctor’s decision. to